Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Pancreatic Neoplasms: HELP
Articles by Valérie Jooste
Based on 6 articles published since 2010
(Why 6 articles?)

Between 2010 and 2020, Valérie Jooste wrote the following 6 articles about Pancreatic Neoplasms.
+ Citations + Abstracts
1 Guideline Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to-event End-points in CANcer trials). 2014

Bonnetain, Franck / Bonsing, Bert / Conroy, Thierry / Dousseau, Adelaide / Glimelius, Bengt / Haustermans, Karin / Lacaine, François / Van Laethem, Jean Luc / Aparicio, Thomas / Aust, Daniela / Bassi, Claudio / Berger, Virginie / Chamorey, Emmanuel / Chibaudel, Benoist / Dahan, Laeticia / De Gramont, Aimery / Delpero, Jean Robert / Dervenis, Christos / Ducreux, Michel / Gal, Jocelyn / Gerber, Erich / Ghaneh, Paula / Hammel, Pascal / Hendlisz, Alain / Jooste, Valérie / Labianca, Roberto / Latouche, Aurelien / Lutz, Manfred / Macarulla, Teresa / Malka, David / Mauer, Muriel / Mitry, Emmanuel / Neoptolemos, John / Pessaux, Patrick / Sauvanet, Alain / Tabernero, Josep / Taieb, Julien / van Tienhoven, Geertjan / Gourgou-Bourgade, Sophie / Bellera, Carine / Mathoulin-Pélissier, Simone / Collette, Laurence. ·Methodology and Quality of Life Unit in Cancer, EA 3181, University Hospital of Besançon and CTD-INCa Gercor, UNICNCER GERICO, Besançon, France. Electronic address: franck.bonnetain@univ-fcomte.fr. · Leiden University Medical Center, Leiden, Netherlands. · Department of Medical Oncology, Institut de Cancérologie de Lorraine, Vandoeuvre-les-Nancy, France. · Bordeaux Segalen University & CHRU, Bordeaux, France. · Department of Radiology, Oncology and Radiation Science, Uppsala University, Uppsala, Sweden. · Department of Radiation Oncology, Leuven, Belgium. · Digestive Surgical Department, Tenon hospital, Paris, France. · Gastro Intestinal Cancer Unit Erasme Hospital Brussels, Belgium. · Gastroenterology Department, Avicenne Hospital, Paris 13, Bobigny, France. · Institute for Pathology, University Hospital Carl-Gustav-Carus, Dresden, Germany. · Surgical and Gastroenterological Department, Endocrine and Pancreatic Unit, Hospital of 'G.B.Rossi', University of Verona, Italy. · Institut de Cancérologie de l'Ouest - Centre Paul Papin Centre de Lutte Contre le Cancer (CLCC), Angers, France. · Biostatistics Unit, Centre Antoine Lacassagne, Nice, France. · Oncology Department, Hôpital Saint-Antoine & CTD-INCa GERCOR, Assistance Publique des Hôpitaux de Paris, UPMC Paris VI, Paris, France. · Gastroenterology Department, Hopital la Timone, Assitance publique des Hopitaux de Marseille, Marseille, France. · Department of Surgery, Institut Paoli Calmettes, Marseille, France. · Department of Surgery, Agia Olga Hospital, Athens, Greece. · Department of Gastroenterology, Institut Gustave Roussy, Villejuif, France. · Biostatistician, Biostatistics Unit, Centre Antoine Lacassagne, Nice, France. · Department of Radiotherapy, Institut fuer Radioonkologie, Vienna, Austria. · Department of Surgical Oncology, Royal Liverpool Hospital, United Kingdom. · Department of Gastroenterology, Beaujon Hospital, Assistance Publique des Hôpitaux de Paris, Paris, France. · Digestive Oncology and Gastro-enterology Department, Jules Bordet Institute, Brussels, Belgium. · Digestive Cancer Registry, INSERM U866, Dijon, France. · Medical Oncology Unit, Ospedali Riuniti di Bergamo, Bergame, Italy. · Inserm, Centre for Research in Epidemiology and Population Health, U1018, Biostatistics Team, Villejuif, France. · Gastroenterology Department, Caritas Hospital, Saarbrücken, Germany. · Department of the Gastrointestinal Tumors and Phase I Unit, Vall d'Hebron University Hospital, Barcelona, Spain. · Statistics Department, EORTC, Brussels, Belgium. · Department of Medical Oncology, Institut Curie, Hôpital René Huguenin, Saint-Cloud, France. · Division of Surgery and Oncology at the University of Liverpool and Royal Liverpool University Hospital, Liverpool, United Kingdom. · Department of Digestive Surgery, Universitu Hospital Strasbourg, France. · Department of Hepato-pancreatic and Biliary Surgery, Beaujon Hospital, Assistance Publique des Hôpitaux de Paris, Paris, France. · Department of Hepato-gastroenterology and Digestive Oncology, Georges Pompidou European hospital, Paris, France. · Department of Radiation Oncology, Academisch Medisch Centrum, Amsterdam, The Netherlands. · Institut Du Cancer de Montpellier, Comprehensive Cancer Centre, and Data Center for Cancer Clinical Trials, CTD-INCa, Montpellier, France. · Clinical and Epidemiological Research Unit, Institut Bergonie, Comprehensive Cancer Centre, Bordeaux, France; Data Center for Cancer Clinical Trials, CTD-INCa, Bordeaux, France; INSERM, Centre d'Investigation Clinique - Épidémiologie Clinique CIC-EC 7, F-33000 Bordeaux, France. ·Eur J Cancer · Pubmed #25256896.

ABSTRACT: BACKGROUND: Using potential surrogate end-points for overall survival (OS) such as Disease-Free- (DFS) or Progression-Free Survival (PFS) is increasingly common in randomised controlled trials (RCTs). However, end-points are too often imprecisely defined which largely contributes to a lack of homogeneity across trials, hampering comparison between them. The aim of the DATECAN (Definition for the Assessment of Time-to-event End-points in CANcer trials)-Pancreas project is to provide guidelines for standardised definition of time-to-event end-points in RCTs for pancreatic cancer. METHODS: Time-to-event end-points currently used were identified from a literature review of pancreatic RCT trials (2006-2009). Academic research groups were contacted for participation in order to select clinicians and methodologists to participate in the pilot and scoring groups (>30 experts). A consensus was built after 2 rounds of the modified Delphi formal consensus approach with the Rand scoring methodology (range: 1-9). RESULTS: For pancreatic cancer, 14 time to event end-points and 25 distinct event types applied to two settings (detectable disease and/or no detectable disease) were considered relevant and included in the questionnaire sent to 52 selected experts. Thirty experts answered both scoring rounds. A total of 204 events distributed over the 14 end-points were scored. After the first round, consensus was reached for 25 items; after the second consensus was reached for 156 items; and after the face-to-face meeting for 203 items. CONCLUSION: The formal consensus approach reached the elaboration of guidelines for standardised definitions of time-to-event end-points allowing cross-comparison of RCTs in pancreatic cancer.

2 Article A new approach to estimate time-to-cure from cancer registries data. 2018

Boussari, Olayidé / Romain, Gaëlle / Remontet, Laurent / Bossard, Nadine / Mounier, Morgane / Bouvier, Anne-Marie / Binquet, Christine / Colonna, Marc / Jooste, Valérie. ·Dijon-Bourgogne University Hospital, Registre Bourguignon des Cancers Digestifs, Dijon F-21000, France; INSERM, U1231, EPICAD team, Univ Bourgogne-Franche-Comté, UMR 1231, Dijon F-21000, France; LabEX LipSTIC, ANR-11-LABX-0021, Dijon F-21000, France. · Dijon-Bourgogne University Hospital, Registre Bourguignon des Cancers Digestifs, Dijon F-21000, France; INSERM, U1231, EPICAD team, Univ Bourgogne-Franche-Comté, UMR 1231, Dijon F-21000, France. · Service de Biostatistique-Bioinformatique, Hospices Civils de Lyon, Lyon F-69003, France; Université de Lyon, Lyon F-69000, France; Université Lyon 1, Villeurbanne F-69100, France; CNRS UMR 5558, Laboratoire de Biométrie et Biologie Évolutive, Équipe Biostatistique Santé, Pierre-Bénite F-69310, France. · Dijon-Bourgogne University Hospital, Univ Bourgogne-Franche-Comté, Registre des Hémopathies Malignes de Côte d'Or, Dijon, France. · INSERM, U1231, EPICAD team, Univ Bourgogne-Franche-Comté, UMR 1231, Dijon F-21000, France; INSERM, CIC1432, Clinical Epidemiology Unit, Dijon F-21000, France; Dijon-Bourgogne University Hospital, Clinical Investigation Centre, Clinical Epidemiology/Clinical Trials Unit, Dijon F-21000, France. · Registre du Cancer de l'Isère, Grenoble University Hospital, Grenoble F-38000, France. · Dijon-Bourgogne University Hospital, Registre Bourguignon des Cancers Digestifs, Dijon F-21000, France; INSERM, U1231, EPICAD team, Univ Bourgogne-Franche-Comté, UMR 1231, Dijon F-21000, France. Electronic address: valerie.jooste@u-bourgogne.fr. ·Cancer Epidemiol · Pubmed #29414635.

ABSTRACT: BACKGROUND: Cure models have been adapted to net survival context to provide important indicators from population-based cancer data, such as the cure fraction and the time-to-cure. However existing methods for computing time-to-cure suffer from some limitations. METHODS: Cure models in net survival framework were briefly overviewed and a new definition of time-to-cure was introduced as the time TTC at which P(t), the estimated covariate-specific probability of being cured at a given time t after diagnosis, reaches 0.95. We applied flexible parametric cure models to data of four cancer sites provided by the French network of cancer registries (FRANCIM). Then estimates of the time-to-cure by TTC and by two existing methods were derived and compared. Cure fractions and probabilities P(t) were also computed. RESULTS: Depending on the age group, TTC ranged from to 8 to 10 years for colorectal and pancreatic cancer and was nearly 12 years for breast cancer. In thyroid cancer patients under 55 years at diagnosis, TTC was strikingly 0: the probability of being cured was >0.95 just after diagnosis. This is an interesting result regarding the health insurance premiums of these patients. The estimated values of time-to-cure from the three approaches were close for colorectal cancer only. CONCLUSIONS: We propose a new approach, based on estimated covariate-specific probability of being cured, to estimate time-to-cure. Compared to two existing methods, the new approach seems to be more intuitive and natural and less sensitive to the survival time distribution.

3 Article Focus on an unusual rise in pancreatic cancer incidence in France. 2017

Bouvier, Anne-Marie / Uhry, Zoé / Jooste, Valérie / Drouillard, Antoine / Remontet, Laurent / Launoy, Guy / Leone, Nathalie / Anonymous4980909. ·Registre Bourguignon des Cancers Digestifs, INSERM, LNC UMR866, F-21000 Dijon, France. · Université Bourgogne Franche-Comté, F-21000 Dijon, France. · CHU Dijon Bourgogne, F-21000 Dijon, France. · FRANCIM (French Network of cancer registries). · Institut de Veille Sanitaire, Département des maladies chroniques et traumatismes, F-94410, Saint-Maurice, France. · Hospices Civils de Lyon, Service de Biostatistique F-69424, France. · Registre des tumeurs digestives du Calvados, INSERM 1086, Centre François Baclesse, Caen F-14076, France. · Registre général des cancers en région Limousin, Hôpital Le Cluzeau, Limoges F-87042, France. ·Int J Epidemiol · Pubmed #28605500.

ABSTRACT: Background: Pancreatic cancer is one of the most lethal. Most countries have exhibited a stable or decreasing incidence over time. The aim of this study was to provide updated French temporal trends in pancreatic cancer incidence and mortality over the past three decades. Methods: Incidence was estimated using the French National Network of Cancer Registries (FRANCIM) and mortality using the French Mortality Statistics Office. World age-standardized incidence and mortality were modelled by age-period-cohort models. The net cumulative risk of developing pancreatic cancer by birth cohort was calculated, as were annual percentage changes (APCs) in incidence and mortality. Results: Between 1982 and 2012, age-standardized incidence increased from 4.8 in 1980 to 9.6 per 100 000 in men and from 2.3 to 6.8 in women. The mean APC was 2.3% (2.1-2.6) and 3.6% (3.3-3.9), respectively. The cumulative risk of developing pancreatic cancer before age 75 rose from 0.62% for males born around 1920 to 1.17% for those born around 1950. It was respectively 0.31% and 0.86% for women. Mortality did not vary in men (8.1 per 100 000). It slightly increased in women from 4.0 in 1982 to 5.4 in 2012. Conclusion: Pancreatic cancer incidence and mortality exhibited diverging trends. Incidence increased over the last 30 years in France whereas mortality did not vary in men and moderately increased in women. Incidence remained lower than mortality up to 2002. One cannot exclude the possibility that a similar trend may appear in other countries. Etiological studies are required to further explain this increase.

4 Article Pancreatic cancer: Wait times from presentation to treatment and survival in a population-based study. 2016

Jooste, Valérie / Dejardin, Olivier / Bouvier, Véronique / Arveux, Patrick / Maynadie, Marc / Launoy, Guy / Bouvier, Anne-Marie. ·CHU Dijon Bourgogne, Registre Bourguignon des Cancers Digestifs, F-21000 Dijon, France; INSERM, LNC UMR866, F-21000 Dijon, France; Université Bourgogne Franche-Comté, LNC UMR866, F-21000 Dijon, France. · University Hospital of Caen, U1086 INSERM UCBN "Cancers & Preventions", Caen, F-14, France. · Breast and Gynaecologic Cancer Registry of Côte D'Or, Centre Georges-François Leclerc Comprehensive Cancer Care Centre, Dijon, F-21, France. · Registre Des Hémopathies Malignes De Côte D'Or, EA4184, University of Burgundy, Dijon, F-21, France. ·Int J Cancer · Pubmed #27130333.

ABSTRACT: Pancreatic survival is one of the worst in oncology. To what extent wait times affect outcomes in unknown No population-based study has previously explored patient and treatment delays among individuals with pancreatic cancer. The aim of this study was to estimate patient and treatment delays in patients with pancreatic cancer and to measure their association with survival in a nonselected population. All patients diagnosed with pancreatic cancer for the first time between 2009 and 2011 and registered in two French digestive cancer registries were included. Patient delay (time from onset of symptoms until the first consultation categorized into <1 or ≥1 month), and treatment delay (time between the first consultation and treatment categorized into less or more than 29 days, the median time) were collected. Overall delay was used to test associations between survival and the timeliness of care by combining patient delay and treatment delay. Patient delay was longer than 1 month in 46% of patients. A patient delay longer than one month was associated with the absence of jaundice (p < 0.001) and the presence of metastasis (p = 0.003). After adjusting for other covariates, such as symptoms and treatment, the presence of metastasis was negatively associated with treatment delay longer than 29 days (p = 0.025). After adjustment for other covariates, especially metastatic dissemination and the result of the resection, overall delay was not significantly associated with prognosis. We found little evidence to suggest that timely care was associated with the survival of patients.

5 Article Rising incidence of pancreatic cancer in France. 2010

Bouvier, Anne-Marie / David, Mathilde / Jooste, Valérie / Chauvenet, Marion / Lepage, Côme / Faivre, Jean. ·Registre Bourguignon des Cancers Digestifs, Centre Hospitalier Universitaire de Dijon, National Institute for Health and Medical Research, and Université de Bourgogne, Dijon, France. Anne-Marie.Bouvier@u-bourgogne.fr ·Pancreas · Pubmed #20881902.

ABSTRACT: OBJECTIVES: Time trends in the incidence of pancreatic cancer vary considerably between countries. The aim of this study was to provide time trends in incidence during a 25-year period in a well-defined French population. METHODS: The cancer registry in Burgundy (France) was used to study time trends between 1981 and 2005 by sex, age, subsite, and histology. They were analyzed using an age-period cohort model. RESULTS: Age-standardized incidence rates increased from 5.7 (1981-1985) to 7.9 per 100,000 (2001-2005) in men and from 2.6 to 4.6 in women. The mean percentage of variation by the 5-year period was +9.9% (P < 0.001, 95% confidence interval, 6.2%-13.6%) and +13.4% (P = 0.004, 95% confidence interval, 9.4%-17.5%), respectively. The increase in incidence was higher for cancers of the tail and corpus than for cancers of the head of pancreas and for malignant pancreatic endocrine tumors than for adenocarcinomas. The cumulative risk of developing a pancreatic cancer rose from 0.51% for men born in 1900 to 1.13% for those born in 1950. It was 0.34% and 0.55% for women, respectively. CONCLUSIONS: The incidence of pancreatic cancer has increased sharply in France both by period and by birth cohort. Etiological studies are required to explain the increase in the incidence.

6 Minor Author's reply to : Pancreatic cancer : Extension of tumor is associated with timeliness of care and with survival in a population-based study. 2018

Jooste, Valérie / Bouvier, Anne-Marie. ·Digestive Cancer Registry of Burgundy, University Hospital of Dijon, INSERM, U1231, University of Burgundy, Dijon, F-21079, France. ·Int J Cancer · Pubmed #29344936.

ABSTRACT: -- No abstract --